Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Adoptive cell transfer and checkpoint blockade have transformed cancer immunotherapy.
• Tumor-specific genetic variations drive T cell-mediated anti-tumour immunity.
• Mutated peptide neoantigens are key targets in personalized cancer medicine.

Purpose of the Study:

• To review the identification and validation of mutated peptide neoantigens.
• To outline bioinformatic and experimental strategies for neoantigen detection and prioritization.
• To examine therapeutic modalities targeting neoantigens for cancer treatment.

Main Methods:

• Review of historical data and scientific literature.
• Analysis of advances in whole exome/genome sequencing and bioinformatics.
• Examination of preclinical and clinical data for neoantigen-targeting therapies.

Main Results:

• Mutated peptide neoantigens are validated targets of the immune system.
• Bioinformatic and experimental strategies effectively detect and prioritize neoantigens.
• Therapeutic modalities targeting neoantigens demonstrate anti-tumour efficacy.

Conclusions:

• Neoantigen-targeted therapies represent a rapidly progressing frontier in personalized cancer medicine.
• Patient-specific and shared neoantigens can be therapeutically targeted.
• Adoptive T cell transfer, checkpoint blockade, and vaccination are key neoantigen-targeting strategies.